Appointment of John B. Parkynn [Parkin] (J.P. Bradley’s brother) to be an Ensign of the 1st Company of the Royal Quebec Volunteers

Appointment of John B. Parkynn [Parkin] (J.P. Bradley’s brother) to be an Ensign of the 1st Company of the Royal Quebec Volunteers. This is signed by the Governor General, the Earl of Gosford and Governor General, Secretary J. Walcott, Nov. 27, 1837.

Memoranda (3 pages, handwritten) with orders to officers of the Royal Quebec Volunteers

Memoranda (3 pages, handwritten) with orders to officers of the Royal Quebec Volunteers regarding their duties at Quebec. This is unsigned, n.d.

Muster roll (1 page, handwritten) of the Royal Quebec Volunteers of Company no. 3 with Captain W. Power

Muster roll (1 page, handwritten) of the Royal Quebec Volunteers of Company no. 3 with Captain W. Power, Lieutenant J.P. Bradley and Ensign C. Allegn, n.d.

Printed Blank of an Orderly Officer’s Report signed by J.P. Bradley, Lieutenant of the Royal Quebec Volunteers

Printed Blank of an Orderly Officer’s Report signed by J.P. Bradley, Lieutenant of the Royal Quebec Volunteers.

Broadside reporting the Fenian Invasion of Canada, June 2, 1866

The Fenians were a group intent on securing Irish independence from England. The movement had its origins in Ireland in1857, under the leadership of James Stephens, with the assistance of John O'Mahony, an American who had raised funds for the cause. The American branch of this movement was especially successful, having raised $500 000 and enlisting about 10 000 American Civil War veterans. The group split into two separate factions, one desiring an invasion of Canada and the other preferring an uprising in Ireland. It soon became apparent that an uprising in Ireland was not imminent, and a decision was made to invade Canada. In April, 1866, a raid was launched against New Brunswick. It proved unsuccessful, and another raid was attempted on June 1, 1866, this time in Ridgeway, near Fort Erie, Ontario. The Canadian militiamen were defeated, but the Fenians subsequently withdrew. A third incident occurred on June 7, this time at Missisquoi Bay in Quebec, when the Fenians crossed the border, remained there for 2 days, and withdrew. A failed uprising in Ireland in 1867 signaled the demise of the movement. The Fenian threat helped to promote a sense of union among Canadians and provided an incentive for Confederation.

Broadside reporting the Fenian Invasion of Canada, June 2, 1866

The Fenians were a group intent on securing Irish independence from England. The movement had its origins in Ireland in1857, under the leadership of James Stephens, with the assistance of John O'Mahony, an American who had raised funds for the cause. The American branch of this movement was especially successful, having raised $500 000 and enlisting about 10 000 American Civil War veterans. The group split into two separate factions, one desiring an invasion of Canada and the other preferring an uprising in Ireland. It soon became apparent that an uprising in Ireland was not imminent, and a decision was made to invade Canada. In April, 1866, a raid was launched against New Brunswick. It proved unsuccessful, and another raid was attempted on June 1, 1866, this time in Ridgeway, near Fort Erie, Ontario. The Canadian militiamen were defeated, but the Fenians subsequently withdrew. A third incident occurred on June 7, this time at Missisquoi Bay in Quebec, when the Fenians crossed the border, remained there for 2 days, and withdrew. A failed uprising in Ireland in 1867 signaled the demise of the movement. The Fenian threat helped to promote a sense of union among Canadians and provided an incentive for Confederation.

Étude technologique et morphologique de la cornéenne dans le sud du Québec : le cas de la carrière préhistorique du mont Royal (BjFj-97) à Montréal.

Le site de la carrière du mont Royal (BjFj-97), découvert en 1993 par Yvon Codère et inventorié en 1997 par l’équipe d’Ethnoscop Inc., constitue une énigme archéologique intéressante pour quiconque s’intéresse à la préhistoire de l’île de Montréal et de sa région adjacente. Lors des activités archéologiques de 1997, quelques idées furent émises quant à son affiliation chronologique et sa nature, suggérant une occupation remontant à l’Archaïque terminal (4000 à 3000 AA) orientée vers l’extraction et la transformation de la cornéenne, une pierre métamorphique résultant de la transformation du substrat rocheux en place suite à des intrusions magmatiques lors du Crétacé qui ont créé les Montérégiennes. Le matériel, comprenant plus de 10 000 déchets de taille et un peu plus de 70 artéfacts divers, ne fît pas l’objet d’analyses poussées hormis la datation approximative du site par un examen sommaire des pointes de projectile. Ce mémoire reprend les données de 1997 et apporte une perspective nouvelle au site en décrivant morphologiquement et technologiquement le débitage de la pierre de façon à comprendre la chaîne opératoire de la cornéenne, une matière peu étudiée, mais fort commune au Québec méridional, appréhender les possibilités de la matière et aborder les questions de datation. L’ensemble du matériel lithique fît l’objet d’une analyse lithique poussée axée sur le débitage et les produits finis et propose la prépondérance de la taille bifaciale, ponctuée par un débitage sur éclat conséquent. L’ensemble des étapes de la chaîne opératoire est présent sur le site de la carrière du mont Royal. La cornéenne est une matière difficile à tailler en raison de son imprévisibilité, liée à la structure même de la matière, menant à un fort taux d’échecs lors de l’élaboration des outils. La datation de l’occupation principale du site pointe vers l’Archaïque terminal, mais le caractère équivoque des diverses classes d’objets rend difficile sa définition absolue, faute d’objets parfaitement diagnostiques. Le site BjFj-97 ressemble grandement à un site homologue en Nouvelle-Angleterre où la cornéenne fût travaillée suivant le même schéma opératoire, suggérant un apparentement culturel possible. La cornéenne abonde et domine dans les assemblages archéologiques de la région montréalaise, substituant ainsi des matières de meilleure qualité absentes régionalement. Leurs correspondances chronologiques transcendent celles établies lors de l’analyse du matériel de la carrière et montrent un étalement chronologiquement plus étendu, de l’Archaïque laurentien au Sylvicole supérieur. La cornéenne se retrouve habituellement sous forme d’outils bifaciaux fonctionnels (bifaces, couteaux et pointes de projectile) de piètre facture et d’outils sur éclats (grattoirs et racloirs) rudimentaires, suggérant une signification strictement utilitaire, le propre des matières de basse qualité. Les modes d’extraction de la cornéenne restent inconnus sur le mont Royal. Le mont Royal est plus qu’un vulgaire point défensif, il constitue la base de la subsistance des populations préhistoriques de jadis où se trouvent les matériaux nécessaires à la taille d’outils de prédation liés à un mode de vie mobile où domine la chasse.

Report [and Plans]; also report on design of Quebec bridge,

Issued also in French.

A Study prepared for the Royal Commission on Dominion Provincial Relations.

Appendixes to: The Report of the Royal Commission on Dominion-Provincial Relations.

Report of the Royal Commission on the Relations of Capital and Labor in Canada.

James Armstrong, chairman 1886 to his death, after which A.T. Freed was chairman.

Report of the Royal commission on the relations of labor and capital in Canada.

Report.--Evidence: Ontario; Quebec; New Brunswick; Nova Scota.

Pharmacokinetic And Pharmacodynamic Evaluation Of A Nanotechnological Topical Formulation Of Lidocaine/prilocaine (nanorap) In Healthy Volunteers.

Nanorap is a new nanotechnological formulation for topical anesthesia composed of lidocaine (2.5%) and prilocaine (2.5%). The present study evaluated the pharmacokinetics (PK) of Nanorap. For the determination of lidocaine and prilocaine in human plasma a new method using high-performance liquid-chromatography coupled to tandem mass spectrometry was developed. Nanorap pharmacodynamic (PD) and its physical proprieties were also evaluated. Nanorap was administered by topical application of 2g to healthy volunteers and blood samples were collected for the PK analysis. The drugs were extracted from plasma by liquid-liquid extraction with ether/hexane (80/20, v/v). The chromatography separation was performed on a Genesis C18 analytical column 4 µm (100 x 2.1 mm i.d.) with a mobile phase of methanol/acetonitrile/water (40/30/30, for lidocaine, and 50/30/20, for prilocaine, v/v/v) + 2 mM of ammonium acetate and ropivacaine as internal standard. The drugs were quantified using a mass spectrometer with an electrospray source in the ESI positive mode (ES+) configured for multiple reaction monitoring. The PD of Nanorap was evaluated with the use of a visual analogue scale. Nanorap was characterized by cryofracture. The chromatography run time was 5.5 min for lidocaine and 3.3 min for prilocaine and the lower limit of quantification was 0.05 ng/mL for both drugs. Mean Cmax was 6.62 and 1.72 ng/mL for lidocaine and prilocaine, respectively. Median Tmax was 6.5 hours for both drugs. Nanocapsules had a mean size of 88nm and mean drug association of 92.5% and 89% for lidocaine and prilocaine, respectively. The PD study showed that Nanorap has a sufficient analgesic effect (>30% reduction in pain) after 10 minutes of application. A new simple, selective and sensitive method for determination of lidocaine and prilocaine in human plasma was developed. Nanorap generated safe plasma levels of the drugs and satisfactory analgesic effect.

Bioequivalence Evaluation of Single Doses of Two Tramadol Formulations: A Randomized, Open-Label, Two-Period Crossover Study in Healthy Brazilian Volunteers

Background: Tramadol is a well tolerated and effective analgesic used to treat moderate to severe pain. Several generic formulations of tramadol are available in Brazil; however, published information regarding their bioequivalence in the Brazilian population is not available. A study was designed for Brazilian regulatory authorities to allow marketing of a generic formulation. Objective: The purpose of this study was to compare the bioequivalence of 2 commercial tablet preparations containing tramadol 100 mg marketed for use in Brazil. Methods: A randomized, open-label, 2 x 2 crossover study was performed in healthy Brazilian volunteers under fasting conditions with a washout period of 12 days. Two tablet formulations of tramadol 100 mg (test and reference formulations) were administered as a single oral dose, and blood samples were collected over 24 hours. Tramadol plasma concentrations were quantified using a validated HPLC method. A plasma concentration time profile was generated for each volunteer and then mean values were determined, from which C(max), T(max), AUC(0-t), AUC(0-infinity), k(e), and t(1/2) were calculated using a noncompartmental model. Bioequivalence between the products was determined by calculating 90% CIs for the ratios of C(max), AUC(0-t), and AUC(0-infinity) values for the test and reference products using log-transformed data. Tolerability was assessed by monitoring vital signs (temperature, blood pressure, heart rate), laboratory tests (hematology, blood biochemistry, hepatic function, urinalysis), and interviews with the volunteers before medication administration and every 2 hours during the study. Results: Twenty-six healthy volunteers (13 men, 13 women) were enrolled in and completed the study. Mean (SD) age was 30 (6.8) years (range, 21-44 years), mean weight was 64 (8.3) kg (range, 53-79 kg), and mean height was 166 (6.4) cm (range, 155-178 cm). The 90% CIs for the ratios of C(max) (1.01-1.17), AUC(0-t) (1.00-1.13), and AUC(0-infinity) (1.00-1.14) values for the test and reference products fell within the interval of 0.80 to 1.25 proposed by most regulatory agencies, including the Brazilian regulatory body. No clinically important adverse effects were reported; only mild somnolence was reported by 4 volunteers and mild headaches by 5 volunteers, and there was no need to use medication to treat these symptoms. Conclusion: Pharmacokinetic analysis in these healthy Brazilian volunteers suggested that the test and reference formulations of tramadol 100-mg tablets met the regulatory requirements to assume bio-equivalence based on the Brazilian regulatory definition. (Clin Ther 2010;32:758-765) (C) 2010 Excerpta Medica Inc.